Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06084780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

Study acronym: TRANSCAPE
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from Case Comprehensive Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Start date: Aug 2026 to Nov 2026
    • Eligibility criteria expanded, about 24 words
    • Site details revised
  2. 2 versions Re-verified since Jun 4, 2026, no change to tracked fieldsv8-v9
  3. Start date: Feb 2026 to Aug 2026v7
  4. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026
    • Start date: Dec 2025 to Feb 2026
    • Site contact updated
    v6
  5. Start date: Aug 2025 to Dec 2025v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Jun 2025 to Aug 2025v4
  2. Start date: Oct 2024 to Jun 2025v3
  3. Start date: Apr 2024 to Oct 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.
Trial Details
NCT Number NCT06084780
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
Related terms Pseudomyxoma Peritonei
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov